• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tao Synergies Inc.

    8/14/25 4:51:57 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    S-8 1 tm2523496d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 14, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    TAO Synergies Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   46-1585656
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         
    1185 Avenue of the Americas, 3rd Floor
    New York, NY
    (Address of Principal Executive Offices)
      10036
    (Zip Code)

     

    TAO Synergies Inc. 2020 Equity Incentive Plan

    (Full title of the plan)

     

    Robert Weinstein

    Chief Financial Officer

    TAO Synergies Inc.

    1185 Avenue of the Americas, 3rd Floor

    New York, NY 1003

    (Name and address of agent for service)

     

    (973) 242-0005

    (Telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Kenneth R. Koch, Esq.

    Daniel A. Bagliebter, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.

    919 Third Avenue

    New York, New York 10022

    212-935-3000 

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed to register an additional 2,000,000 shares of common stock, par value $0.0001 per share, of TAO Synergies Inc. (the “Registrant”) reserved for issuance under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”), which were added to the shares authorized for issuance under the 2020 Plan pursuant to an amendment to the 2020 Plan adopted by the Registrant’s stockholders on August 6, 2025. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to an employee benefit plan is effective (File No. 333-258807). The information contained in the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 13, 2021 (File No. 333-258807) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Filed
    Here
    with
      Incorporated
    by
    Reference

    herein
    from

    Form or
    Schedule
      Filing
    Date
      SEC File/
    Reg.
    Number
                         
    4.1   Form of Common Stock Certificate of the Registrant       Form S-1/A (Exhibit 4.5)   11/05/2020   333-249434
                         
    5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of the securities being registered    X            
                         
    23.1   Consent of Stephano Slack LLC    X            
                         
    23.2   Consent of Morison Cogen LLP    X            
                         
    23.3   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)    X            
                         
    24.1   Power of Attorney (included on signature page to this Registration Statement)    X            
                         
    107   Filing Fee Table    X            

      

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on August 14, 2025.

     

      TAO SYNERGIES INC.
       
      By: /s/ Robert Weinstein
        Robert Weinstein
        Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each of the directors and officers of TAO Synergies Inc. whose signature appears below hereby severally constitutes and appoints Joshua Silverman and Robert Weinstein, and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of TAO Synergies Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Joshua Silverman   Executive Chairman and Director   August 14, 2025
    Joshua Silverman   (Principal Executive Officer)    
             
    /s/ Robert Weinstein   Chief Financial Officer   August 14, 2025
    Robert Weinstein   (Principal Financial and Accounting Officer)    
             
    /s/ Alan J. Tuchman, M.D.   Director   August 14, 2025
    Alan J. Tuchman, M.D.        
             
    /s/ William S. Singer   Director and Vice-Chairman of the Board   August 14, 2025
    William S. Singer        
             
    /s/ Bruce T. Bernstein   Director   August 14, 2025
    Bruce T. Bernstein        
             
    /s/ Jonathan L. Schechter   Director   August 14, 2025
    Jonathan L. Schechter        

     

     

     

    Get the next $TAOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    SEC Filings

    View All

    SEC Form S-8 filed by Tao Synergies Inc.

    S-8 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:51:57 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tao Synergies Inc.

    S-3 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:50:01 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tao Synergies Inc.

    10-Q - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:19:26 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies Accelerates Decentralized AI Treasury Strategy with 42,111 Bittensor (TAO) Tokens Acquired and Earned Through Staking to Date

    Largest publicly traded TAO pure-play treasury company TAO treasury strategy anchored at intersection of decentralized AI and cryptocurrencies NEW YORK, Aug. 6, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that, as of August 5th, 2025, it has accumulated 42,111 Bittensor (TAO) tokens to date as part of its differentiated digital asset treasury strategy. "Our TAO-focused crypto strategy is anchored at the intersection of decentralized AI and blockchain," stated TAO Synergies' Executive Chairman Joshua Silverman. "In

    8/6/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care